摘要
2006年意大利针对高值药品实施绩效风险分担协议,该政策的实施有效提高了重特大疾病患者的可负担性与药物可及性,同降低了政府财政负担。目前,我国正探索实施高值药品谈判政策,通过介绍意大利绩效风险分担协议的背景、主要内容、谈判流程以及政策,以期为我国高值药品谈判政策的实施提供参考。
In 2006, Italy has implemented Good Practices for Performance-Based Risk-Sharing Anangements（PBRSAs） for high value drugs for critical illnesses. The implementation of policy effectively increased the affordability and availability of drugs for critical illness and reduced the financial burden of government. In current, China is exploring the negotiation policy of high value drugs tor critical illnesses. The background, main content, negotiation process and policy of Italy＇ s PBRSAs were introduced to provide references for the implementation of China＇s PBRSAs.
出处
《中国卫生经济》
北大核心
2016年第11期94-96,共3页
Chinese Health Economics
关键词
高值药品
绩效风险分担协议
意大利
high value drugs
good practices for performance-based risk-sharing arrangements
Italy
